Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teicoplanin prophylaxis for infection prevention in children with newly diagnosed acute myeloid leukemia
NL-OMON54113Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of teicoplanin in acute myeloid leukemia (AML), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Dose-limiting toxicities and Viridans group streptococcal bloodstream infection. Started May 2021; status: recruiting.
02
Drugs
teicoplanin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON54113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54113.